What generic anti‑obesity medications are recommended for adults with a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with obesity‑related conditions), including their dosing, contraindications, and monitoring requirements?

Choosing Anti-Obesity Medications: Generic Options

For adults with obesity (BMI ≥30 kg/m²) or overweight with complications (BMI ≥27 kg/m²) who have failed lifestyle interventions, add pharmacotherapy to lifestyle modifications, with phentermine as the primary generic option and orlistat as a second-line alternative despite its limited efficacy. 1

Algorithmic Approach to Generic Anti-Obesity Medications

First-Line Generic Option: Phentermine

Phentermine monotherapy is the most accessible generic anti-obesity medication, though it carries a conditional recommendation with low-quality evidence 1. Despite FDA approval for only 12 weeks, many practitioners use it off-label for longer durations given obesity's chronic nature 1.

Dosing:

• Standard dosing varies by formulation (typically 15-37.5 mg daily)
• Take in the morning to avoid insomnia

Key Contraindications:

• History of cardiovascular disease (absolute contraindication) 1
• Uncontrolled hypertension
• Hyperthyroidism
• Glaucoma
• History of drug abuse

Monitoring Requirements:

• Blood pressure and heart rate periodically 1
• Assess for cardiovascular symptoms
• Evaluate weight loss response at 12 weeks

Second-Line Generic Option: Orlistat

The AGA actually suggests AGAINST using orlistat due to minimal weight loss benefit (only 3.1% greater than placebo) and significant gastrointestinal adverse effects 1, 2. However, it remains an option for patients who highly value even small weight loss and can tolerate GI side effects 1.

Dosing:

• 120 mg three times daily with meals containing fat 3
• 60 mg formulation available over-the-counter

Key Side Effects:

• Oily fecal spotting and urgency in >25% of patients 2
• Fecal incontinence
• Flatulence with discharge

Monitoring Requirements:

• Mandatory daily multivitamin containing fat-soluble vitamins (A, D, E, K) taken 2 hours apart from orlistat 1
• Monitor for fat-soluble vitamin deficiency
• Assess weight loss at 12 weeks

Contraindications:

• Chronic malabsorption syndrome
• Cholestasis

Generic Combination Therapy Components

While phentermine-topiramate ER and naltrexone-bupropion ER are FDA-approved combinations with stronger evidence (conditional recommendations, moderate quality) 1, the individual generic components are not recommended as separate prescriptions for obesity outside these specific formulations.

Phentermine-Topiramate ER (if accessible as generic combination)

• Preferentially use in patients with comorbid migraines 1
• Avoid in cardiovascular disease and uncontrolled hypertension 1
• Topiramate is teratogenic—women of childbearing potential require consistent effective contraception 1
• Monitor blood pressure and heart rate periodically 1

Naltrexone-Bupropion ER (if accessible as generic combination)

• Consider for patients attempting smoking cessation or with depression 1
• Avoid in seizure disorders; use caution in patients at seizure risk 1
• Cannot use concomitantly with opiate medications 1
• Monitor blood pressure and heart rate, especially first 12 weeks 1

Critical Decision Points

When to discontinue therapy:

• Weight loss <5% (approximately 4-5 kg) after 12 weeks should prompt cessation 4
• Development of contraindications
• Intolerable side effects

Common Pitfalls to Avoid:

1. Cardiovascular screening failure: Always exclude cardiovascular disease before prescribing phentermine 1

2. Forgetting vitamin supplementation with orlistat: This is mandatory, not optional 1

3. Short-term thinking: Obesity is a chronic disease requiring long-term pharmacotherapy 1. The 12-week FDA approval for phentermine reflects outdated thinking, though off-label extended use requires careful cardiovascular monitoring 1

4. Ignoring the evidence hierarchy: While phentermine is the most accessible generic option, branded medications like semaglutide 2.4 mg (11.4% greater weight loss) and liraglutide 3.0 mg (4.7% greater weight loss) have substantially better efficacy than phentermine or orlistat 2. Cost and access should not override clinical efficacy when morbidity and mortality are at stake.

The Reality of Generic Options

The evidence strongly favors newer branded medications over generic options 1, 2. Semaglutide 2.4 mg may be prioritized over other approved anti-obesity medications given its magnitude of benefit 1. Generic options represent compromises driven by cost rather than optimal clinical outcomes. When prescribing generic medications, set realistic expectations: phentermine has low-quality evidence, and orlistat is actively recommended against by major guidelines 1.

All anti-obesity medications must be combined with lifestyle interventions—this is non-negotiable for efficacy 1, 3.